The Online Investor
PDLI Buyback image

PDL BioPharma, Inc Buyback

OLI recorded this information on 9/24/2018

Company: PDL BioPharma, Inc
Buyback: PDLI buyback
$Amount Authorized: $100,000,000
Buyback Details: PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock. Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission.

PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.
Open the PDLI Page at The Online Investor »

Company Name: 
PDL BioPharma Inc
Stock buyback: 
PDLI buyback
Rental, Leasing, & Royalty

Open the PDLI Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PDLI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
PDLI Stock Forecast

Based on Zacks ABR data;
powered by Xignite

PDLI Buyback Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.